To synthesize current evidence regarding the role of EGFR ligands in regulating beta cell mass, insulin secretion, hepatic gluconeogenesis, and peripheral insulin sensitivity, highlighting their potential significance in diabetes treatment.
Key Findings:
EGFR ligands, including EGF, TGFα, and others, play a significant role in insulin secretion and beta cell mass regulation.
EGF administration stimulates insulin secretion through calcium influx and phospholipase D activation.
EGFR activation promotes beta cell proliferation and survival, with potential implications for diabetes treatment.
EGFR TKIs can lead to hyperglycemia, necessitating management strategies in patients, highlighting a metabolic paradox.
Interpretation:
While rodent studies suggest a role for EGFR in glucose homeostasis, human data remain observational and inconclusive, necessitating further exploration of their implications.
Limitations:
Current findings are primarily based on in vitro and animal studies, lacking robust human clinical validation, which is crucial for translating these findings into clinical practice.
Observational data on endogenous EGF levels and diabetes progression in humans are inconclusive, underscoring the need for targeted clinical trials.
Conclusion:
The review highlights the need for further translational research to clarify the role of EGFR ligands in glucose metabolism, particularly through human clinical trials and mechanistic studies.
A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.
